CervoMed Inc. (CRVO)

NASDAQ: CRVO · Real-Time Price · USD

8.08

-0.40 (-4.72%)

Dec 26, 2025, 4:00 PM EST - Market closed

CervoMed Employees

CervoMed had 15 employees as of December 31, 2024. The number of employees increased by 7 or 87.50% compared to the previous year.

Employees

15

Change (1Y)

7

Growth (1Y)

87.50%

Revenue / Employee

$410,652

Profits / Employee

-$1,705,666

Market Cap

74.76M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	15	7	87.50%
Dec 31, 2023	8	4	100.00%
Dec 31, 2022	4	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

CRVO News

23 days ago - CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewsWire
26 days ago - CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - GlobeNewsWire
4 weeks ago - CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
2 months ago - CervoMed to Present at the Emerging Growth Conference - GlobeNewsWire
2 months ago - CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - Benzinga
2 months ago - CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies - GlobeNewsWire
3 months ago - CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
3 months ago - CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference - GlobeNewsWire